The Lead Episode 172: A Discussion of Integrated Care Management and Comprehensive Geriatric Assessment Using a mHeath-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO Cluster-Randomized Trial

In this episode of The Lead, host Melissa E. Middeldorp, MPH, PhD, FHRS, is joined by David J. Slotwiner, MD, FHRS, and Alessandra Pina, MBBS, MD, to discuss "Integrated Care Management and Comprehensive Geriatric Assessment Using an mHealth-Based Approach in Older Multimorbid Patients With Atrial Fibrillation: The AFFIRMO Cluster Randomised Trial." The panel examines the trial's evaluation of an mHealth-based integrated care approach for older patients with atrial fibrillation and comorbidities, exploring its neutral effect on hospitalization, challenges with patient engagement, characteristics of the study population, and implications for developing and implementing digital health interventions.

Learning Objectives:

1. Describe the design, patient population, integrated care intervention, and clinical outcomes of the AFFIRMO cluster randomized trial.

2. Evaluate factors that may have contributed to the trial's neutral primary outcome, including characteristics of the study population, baseline management of atrial fibrillation, and patient engagement with the mHealth intervention.

3. Assess the opportunities and challenges associated with using mHealth tools to support integrated atrial fibrillation and comorbidity management in older adults.

Podcast Contributors

Host: Melissa E. Middeldorp, MPH, PhD, FHRS

Guests: David J. Slotwiner, MD, FHRS and Alessandra Pina, MBBS, MD

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

M. Middeldorp

• Nothing to disclose

D. Slotwiner

• Nothing to disclose
  
  

A. Pina

• Nothing to disclose

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
M. Baldwin: No relevant financial relationships with ineligible companies to disclose.